DE69839566D1 - Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten - Google Patents

Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten

Info

Publication number
DE69839566D1
DE69839566D1 DE69839566T DE69839566T DE69839566D1 DE 69839566 D1 DE69839566 D1 DE 69839566D1 DE 69839566 T DE69839566 T DE 69839566T DE 69839566 T DE69839566 T DE 69839566T DE 69839566 D1 DE69839566 D1 DE 69839566D1
Authority
DE
Germany
Prior art keywords
fragment
shigatoxin
peptides
chimeric polypeptides
polypeptides containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839566T
Other languages
English (en)
Inventor
Bruno Goud
Ludger Johannes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Curie
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Curie filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE69839566D1 publication Critical patent/DE69839566D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69839566T 1997-07-18 1998-07-17 Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten Expired - Lifetime DE69839566D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9709185A FR2766193B1 (fr) 1997-07-18 1997-07-18 Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
PCT/FR1998/001573 WO1999003881A2 (fr) 1997-07-18 1998-07-17 Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique

Publications (1)

Publication Number Publication Date
DE69839566D1 true DE69839566D1 (de) 2008-07-10

Family

ID=9509394

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839566T Expired - Lifetime DE69839566D1 (de) 1997-07-18 1998-07-17 Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten

Country Status (13)

Country Link
US (4) US6613882B1 (de)
EP (1) EP1017715B1 (de)
JP (2) JP4541538B2 (de)
CN (1) CN1272882A (de)
AT (1) ATE397062T1 (de)
AU (1) AU750367B2 (de)
CA (1) CA2296711C (de)
DE (1) DE69839566D1 (de)
DK (1) DK1017715T3 (de)
ES (1) ES2307323T3 (de)
FR (1) FR2766193B1 (de)
HK (1) HK1030613A1 (de)
WO (1) WO1999003881A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081307A1 (en) * 1998-05-15 2002-06-27 Allan M. Green Verotoxin b subunit for immunization
EP1057895A1 (de) * 1999-06-04 2000-12-06 Lohmann Animal Health GmbH & Co. KG Fusionsprotein das das Fragment B des Shigatoxins enthält, dieses enthaltende (Impf-)Stoffzusammensetzung und Verfahren zu dessen Herstellung
US20040071739A1 (en) * 1999-11-15 2004-04-15 Select Therapeutics, Inc. Methods of preparing an anti-tumor vaccine
EP1229045A1 (de) 2001-02-01 2002-08-07 Institut Curie Universeller Träger zum Zielrichten von Molekülen zu Rezeptor Gb3 - exprimierenden Zellen
EP1386927B1 (de) * 2002-08-02 2005-03-30 Institut Curie Shiga-Toxin-Untereinheit B als Vektor zur Diagnose von Tumoren und zur Arzneimittelverabreichung an GB3-exprimierenden Tumoren
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
EP2308514B1 (de) * 2007-03-23 2013-06-05 to-BBB Holding B.V. Konjugate zum Arzneimitteltransport über die Blut-Hirn-Schranke
EP2072060A1 (de) 2007-12-18 2009-06-24 Institut Curie Verfahren und Zusammensetzungen zur Herstellung und Verwendung von Toxinkonjugaten
US20090214438A1 (en) * 2007-12-18 2009-08-27 Institut Curie Methods and compositions for the preparation and use of toxin conjugates
CN102986214A (zh) 2010-07-06 2013-03-20 皇家飞利浦电子股份有限公司 从低动态范围图像生成高动态范围图像
EP2548571A1 (de) 2011-07-22 2013-01-23 Institut Curie Zusammensetzungen mit Mitteln zum Targeting von mindestens einem Antigen zu dendritischen Zellen
EP2740493A1 (de) 2012-12-05 2014-06-11 Institut Curie Konjugate der B-Untereinheit von Shiga-Toxin für Antikrebstherapien
EP2740491A1 (de) 2012-12-05 2014-06-11 Institut Curie Konjugate der B-Untereinheit von Shiga-Toxin zur Verwendung als Kontrastmittel zur Bildgebung und Therapie
EP3868776A1 (de) 2014-01-27 2021-08-25 Molecular Templates, Inc. Mhc-klasse-i-epitope freisetzende polypeptide
EP3058956A1 (de) 2015-02-23 2016-08-24 Institut Curie Kombinierte Impfungs-/Strahlentherapie zur Krebsbehandlung
CN104744594B (zh) * 2015-04-21 2018-09-18 中国人民解放军第三军医大学 乙肝病毒多表位与志贺毒素的融合蛋白及其制备方法和应用
RS60441B1 (sr) * 2015-05-30 2020-07-31 Molecular Templates Inc De-imunizovane, strukture shiga toksin a podjedinice i ciljani ćelijski molekuli koji sadrže isti
EP3325510A2 (de) * 2015-07-26 2018-05-30 Molecular Templates, Inc. Gegen zellen gerichtete moleküle mit effektoren der shigatoxin-a-untereinheit und cd8+-t-zellepitopen
IL302130A (en) 2016-12-07 2023-06-01 Molecular Templates Inc Shiga toxin A subunit activator polypeptides, Shiga toxin activator scaffolds and cell-targeting molecules for site-specific conjugation
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
WO2019204272A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
CN116236584B (zh) * 2023-02-20 2024-03-22 四川大学 一种用于高效递送siRNA的多糖-多肽偶联物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2547731A1 (fr) 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US5198344A (en) 1986-07-15 1993-03-30 Massachusetts Institute Of Technology DNA sequence that encodes the multidrug resistance gene
US5338839A (en) 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
WO1991009871A1 (en) 1989-12-22 1991-07-11 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region
KR910014970A (ko) 1990-01-08 1991-08-31 미다 가쓰시게 가스 차단기
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
CA2077277A1 (en) 1991-09-09 1993-03-10 John J. Donnelly Cellular immunity vaccines from bacterial toxin-antigen conjugates
DE4219696A1 (de) * 1992-02-17 1993-08-19 Biotechnolog Forschung Gmbh Hybrid-dna, plasmide, oligohybridpeptid und impfstoff
AU3628193A (en) * 1992-02-18 1993-09-13 Gesellschaft Fur Biotechnologische Forschung Mbh Dysentery vaccine stimulating an immune response against shigatoxin, plasmids and host strains for it
US5350890A (en) 1992-10-01 1994-09-27 Gould Instrument Systems, Inc. Contact switch device
EP0692031B1 (de) 1993-02-22 2007-04-11 The General Hospital Corporation Heterologe antigene in stämmen zur impfung mit lebendzellen
US7229755B1 (en) 1993-11-17 2007-06-12 Dana Farber Cancer Institute, Inc. Method for detection of alterations in the DNA mismatch repair pathway
US5763165A (en) 1994-03-10 1998-06-09 Ludwig Institute For Cancer Research Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
AU3876795A (en) 1994-11-17 1996-06-17 Maxim Pharmaceuticals, Inc. Immunogens for stimulating mucosal immunity
EP0739984A1 (de) 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalente Polypeptiden die mindestens zwei Bereichen enthalten
WO1997013410A1 (en) * 1995-10-13 1997-04-17 Boston Medical Center Corporation Hybrid molecules containing amidated polypeptide binding ligands
AR010218A1 (es) 1996-09-10 2000-06-07 Military Henry M Jackson Foundation For The Advancement Of Una familia de proteinas bacterianas multi-unidad
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6482586B1 (en) 1996-11-22 2002-11-19 Hospital For Sick Children Research And Development Limited Partnership Hybrid compositions for intracellular targeting
US20020081307A1 (en) 1998-05-15 2002-06-27 Allan M. Green Verotoxin b subunit for immunization

Also Published As

Publication number Publication date
JP2010180216A (ja) 2010-08-19
AU750367B2 (en) 2002-07-18
FR2766193B1 (fr) 2001-09-14
CA2296711A1 (fr) 1999-01-28
US20170015719A1 (en) 2017-01-19
WO1999003881A2 (fr) 1999-01-28
DK1017715T3 (da) 2008-10-06
EP1017715B1 (de) 2008-05-28
JP4541538B2 (ja) 2010-09-08
JP2001510030A (ja) 2001-07-31
HK1030613A1 (en) 2001-05-11
ES2307323T3 (es) 2008-11-16
CN1272882A (zh) 2000-11-08
US20040047883A1 (en) 2004-03-11
US20100322913A1 (en) 2010-12-23
US6613882B1 (en) 2003-09-02
US8524652B2 (en) 2013-09-03
US7488809B2 (en) 2009-02-10
EP1017715A2 (de) 2000-07-12
FR2766193A1 (fr) 1999-01-22
WO1999003881A3 (fr) 2000-06-29
ATE397062T1 (de) 2008-06-15
CA2296711C (fr) 2012-07-03
AU8812498A (en) 1999-02-10

Similar Documents

Publication Publication Date Title
DE69839566D1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
NO20100324L (no) Fremgangsmate for trinnvis festing av polyetylenglykol (PEG) andeler i serie til et polypeptid
ATE428785T1 (de) Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
ATE395417T1 (de) Pestizid toxine
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
HUT77049A (hu) Katepszin-02-fehérjék, -nukleinsavak és -ellenanyagok
DK72593D0 (da) Rekombinant protein
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
DE69434384D1 (de) Metalkomplexbildner
BR9607583B1 (pt) plasmìdios procarióticos recombinantes.
ATE273388T1 (de) Veränderte menschliche c3-proteine
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE291080T1 (de) Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
DE69938130D1 (de) Neue peptide
DK0968288T3 (da) z219a, en human homolog til 2-19 protein
DE69504795D1 (de) Methoden zur synthese und reinigung von peptiden
DK0833919T3 (da) Type F botulintoksin og anvendelse deraf
TR26073A (tr) Bacillus thuringiensis jenleri,toksinleri ve insektisid olarak kullanimlari.
DE69535380D1 (de) Humaner kappa opiatrezeptor, nukleinsäuren und ihre verwendungen
DE69534738D1 (de) Leukocyten-aktivierender Faktor
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
ATE75255T1 (de) Peptid und dafuer kodierendes gen.
AU5311701A (en) Novel human neurexin-like proteins and polynucleotides encoding the same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition